EUCTR2022-000666-17-DE
进行中（未招募）
1 期
A Phase II double-blind, randomised, placebo-controlled study of efficacy and safety of Vibrio alginolyticus collagenase administered to patients with Dupuytren contracture - Vibrio alginolyticus collagenase Phase II
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Dupuytren contracture
- 发起方
- Fidia Farmaceutici Spa
- 入组人数
- 72
- 状态
- 进行中（未招募）
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Informed consent: signed written informed consent before inclusion in the study
- •2\. Sex and Age: men/women, \=18 year old inclusive
- •3\. Dupuytren contracture: diagnosis of Dupuytren contracture with a fixed flexion deformity \=20° and \=100°, if in a MP joint, or \=20° and \=80°, if in a PIP joint, of at least one finger, other than the thumb, caused by a palpable cord that, according to the investigator’s judgement, could benefit from treatment with collagenase
- •4\. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co\-operate with the investigator and to comply with the requirements of the entire study
- •5\. Contraception and fertility (women only): women of child\-bearing potential must be using at least one of the following reliable methods of contraception:
- •a. Hormonal oral, implantable, transdermal or injectable contraceptives for at least 2 months before the screening visit
- •b. A non\-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
- •c. A male sexual partner who agrees to use a male condom with spermicide
- •d. A sterile sexual partner
- •e. Sexual abstinence
排除标准
- •1\. Previous Dupuytren contracture treatments: previous treatments of Dupuytren contracture including needle aponeurotomy (percutaneous needle fasciotomy) or injection of verapamil or interferon on the selected primary joint
- •2\. Previous Dupuytren contracture surgical treatments: previous fasciectomy or surgical fasciotomy in the primary joint hand
- •3\. Previous treatment with Clostridium histolyticum or Vibrio alginolyticus collagenase
- •4\. Hand disorders: chronic muscular, neurological or neuromuscular disorders affecting hands
- •5\. Bleeding and anticoagulants: history of bleeding or anticoagulant therapy within 7 days of the screening with the exception of daily intake of aspirin
- •6\. Allergy: ascertained or presumptive hypersensitivity to collagenase and/or formulation diluent and/or excipients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
- •7\. Diseases: significant history of cardiovascular diseases including known recent history of stroke or skin diseases, or endocrine or neurological diseases that affected the hands or of any other medical condition which in the investigator’s opinion may interfere with the aim of the study
- •8\. Medications: intake of tetracyclines, anthracycline derivatives, quinolones or fluoroquinolones within 14 days before the screening
- •9\. Investigative drug studies: participation in the evaluation of any investigational product for 30 days before this study
- •10\. Pregnancy (women of child\-bearing potential only): positive or missing pregnancy test at screening or Day 1, pregnant or lactating women
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Phase II study with placebo to evaluate the efficacy and safety of bacterial collagenase administered in patients with Dupuytren's contractureDupuytren contractureMedDRA version: 20.0Level: PTClassification code 10013872Term: Dupuytren's contractureSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2022-000666-17-ATFidia Farmaceutici Spa72
进行中（未招募）
不适用
europrotection with phenytoin in optic neuritisAcute demyelinating optic neuritisMedDRA version: 16.0Level: PTClassification code 10030942Term: Optic neuritisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-003475-11-GBniversity College London (UCL)
进行中（未招募）
不适用
A Phase II randomised, double-blind, placebo-controlled, incompletecrossover trial with 4-week treatment periods to evaluate efficacy andsafety of tiotropium inhalation solution (doses of 1.25µg, 2.5µg and 5µg) delivered via Respimat® inhaler once daily in the evening in adolescents(12 to 17 yrs old) with moderate persistent asthmaModerate persistent asthma in adolescents (12 to 17 years old)MedDRA version: 12.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2009-017745-55-LVBoehringer Ingelheim Pharma GmbH & Co. KG92
进行中（未招募）
不适用
A Phase II randomised, double-blind, placebo-controlled, incompletecrossover trial with 4-week treatment periods to evaluate efficacy andsafety of tiotropium inhalation solution (doses of 1.25µg, 2.5µg and 5µg) delivered via Respimat® inhaler once daily in the evening in adolescents(12 to 17 yrs old) with moderate persistent asthmaModerate persistent asthma in adolescents (12 to 17 years old)MedDRA version: 12.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2009-017745-55-DEBoehringer Ingelheim Pharma GmbH & Co. KG92
招募中
2 期
A Phase II randomised, double-blind, placebo-controlled trial of S-Adenosyl Methionine (SAMe) in participants with mild cognitive impairment or dementia due to Alzheimer’s diseaseAlzheimer's diseaseMild Cognitive ImpairmentNeurological - Alzheimer's diseaseMental Health - Other mental health disordersACTRN12620000506998The University of Melbourne60